- Tags: cornea
Pipeline
FDA grants TearSolutions' NK peptide therapy two FDA designations
Investigational eye drop acts as a replacement for lacritin by restoring homeostasis to the ocular surface; phase 2 trial initiation is underway.
Products
CMS assigns Glaukos’ Epioxa a permanent J-code
Corneal CXL therapy was approved in October 2025 as the first topical drug not requiring removal of the corneal epithelium for keratoconus treatment.
Pipeline
Aurion Biotech begins dosing in phase 3 trial on allogeneic cell therapy for CED
The ASTRA study kicks off evaluating AURN001, designed to regenerate corneal clarity and vision through an intracameral injection.
Products
FDA clears the OCULUS Pentacam Cornea OCT
Diagnostic device combines OCT and Schleimpflug imaging to provide advanced cornea visualization via a single, 1-second measurement process.
Pipeline
Lineage Cell Therapeutics launches new CED cell therapy program
Preclinical candidate COR1 is designed as an allogeneic source of corneal endothelial cells to replace damaged cells and restore corneal function.
Research
TED may cause reduced stromal corneal thickness
Study findings indicate association with layer-specific corneal structural changes.
Products
Glaukos' Epioxa now commercially available in the US
Corneal CXL therapy was approved as the first topical drug therapy not requiring removal of the corneal epithelium for keratoconus treatment.
Research
Could rhNGF treatment benefit long-term NK corneal recovery?
Study identifies unique limbal epithelial stem cell findings associated with neurotrophic keratitis and long-term efficacy of cenegermin.
Research
Case reports indicate positive outcomes of CAM for OSD management
Real-world evidence supports BioTissue’s Prokera Slim and CAM360 AmnioGraft cryopreserved amniotic membrane devices in two patient cases.
Events
Registration opens for Corneal Health Summit 2026
Kicking off April 4, the virtual half-day program focuses on early detection and intervention in corneal disease—with up to 3 hours of COPE-accredited CE.
Pipeline
Pandorum Tech raises $18M to expand operations for bioengineered cornea
Financing to advance biotech’s ‘liquid-based cornea’ Kuragenx, an eye drop bioengineered to revert an ulcerative cornea to its healthy state in less than 1 year.
Products
WAVE Lens Designer Software integrates with Topcon MYAH
Integration enables direct import of corneal topography data into custom lens platform, streamlining the specialty contact lens design workflow.
Pipeline
FDA approves Allotex's IDE for US study of tissue-based solution for presbyopia
Company gets all-clear for clinical trial on its tissue addition technology and customized, laser-shaped human corneal tissue to restore vision.
Pipeline
OKYO Pharma reports favorable phase 2 data for NCP asset
Formerly OK-101, urcosimod is formulated for topical application, with latest results demonstrating a favorable impact on corneal nerve health.
Pipeline
EyeYon Medical secures IDE approval for study on first artificial endothelial layer
IDE approval allows for clinical study initiation to evaluate EndoArt, the first-ever synthetic implant for treating corneal edema and improving vision.
Pipeline
Precise Bio performs first transplant with 3D-printed cornea implant
Procedure deemed successful in treating first fully blind patient using corneal bio-implant made from corneal endothelial cells.
Research
Study identifies key vitamin supplementation for NCP
Vitamins B3, 12, and D may offer new therapeutic approaches to neuropathic corneal pain management.
Research
Nearly 50% of adults with keratoconus still facing high rate of progression
Study finds, across all age groups, patients with advanced disease were most at risk of keratoconus progression.Research
Study: BioTissue's CAM improves recovery following corneal CXL
Research from AAO supports BioTissue’s Prokera as an FDA-cleared therapeutic device for use following epi-off CXL among keratoconus patients.
Business